U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT07587385) titled 'A Study of HS-10506 in Chinese Patients With Insomnia Disorder' on April 23.
Brief Summary: The primary purpose of this phase 3 study is to evaluate the safety and the efficacy of HS-10506 (change versus placebo) on latency to persistent sleep (LPS) and wakefulness after sleep onset (WASO) measured by polysomnography (PSG) in Chinese adult participants with insomnia disorder.
Study Start Date: May 29
Study Type: INTERVENTIONAL
Condition:
Insomnia Disorder
Intervention:
DRUG: HS-10506
HS-10506 tablet
DRUG: Placebo
Placebo tablet matched to HS-10506
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Jiangsu Hansoh Pharmaceutica...